Have your symptoms returned?

There are 2 goals of treatment for inflammatory bowel disease (IBD). The first goal is to achieve remission. Remission is when symptoms of a disease go away. Once remission is achieved, the second goal of treatment is to stay in remission. This means that symptoms do not return. A return of symptoms is called a flare-up.

If you have IBD, you might be taking medicines such as corticosteroids, aminosalicylates, immunomodulators, or antibiotics. Or you may be on treatment with biologics (biologic therapies), the newest type of treatment for people who have not responded well to other therapies. Examples of biologics are Remicade® (infliximab) and Humira® (adalimumab).

If you are on treatment with Remicade or Humira, your IBD symptoms may return even if you are taking your medicine the way your healthcare provider told you to. This is called loss of response. If you have a loss of response:

  • You may not have enough Remicade or Humira in your body. Having the right amount of medicine in your system makes loss of response less likely
  • Your body may have developed antibodies that “fight” against the medicine. These antibodies prevent the medicine from working the right way
  • You may have an infection or another medical condition that is causing your symptoms and is not related to your treatment with Remicade or Humira

It can be discouraging if your IBD symptoms return. You want to feel better as soon as possible. If you have symptoms, ask your healthcare provider about PROMETHEUS® Anser™ tests. These tests may help your healthcare provider figure out the best plan of action for you. Your healthcare provider might suggest one or more of these things:

  • Changing the amount of medicine you take
  • Changing how often you take your medicine
  • Prescribing a different medicine for you
  • Finding other causes of your symptoms (if you have the right amount of Remicade or Humira in your body)

Remicade is a registered trademark of Janssen Biotech, Inc.
Humira is a registered trademark of AbbVie Inc.